Antibody–drug conjugates at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
14 organizations at Antibody Engineering 2026 present work in adcs & conjugates: 6 drug developers, 5 suppliers and service providers and 3 academic, government and non-profit bodies. Between them they bring 17 presentations to the program. Most represented: AstraZeneca (3 on the program), City of Hope (2 on the program), Invenra (1 on the program). 7 of them have their own page in this guide. As of Sep 26, 2026.
Format
Top represented
Showing 1–14 of 14 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases. | Talk Sun Dec 13 11:00am–11:45am Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Talk Wed Dec 16 2:10pm–2:15pm Talk Wed Dec 16 2:15pm–2:45pm |
City of Hope Duarte, CA | |
Cancer research and treatment center with a graduate school. | Talk Wed Dec 16 3:15pm–3:45pm MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody. Bispecifics & multispecifics Talk Wed Dec 16 4:15pm–4:45pm Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors. |
Invenra Madison, WI | |
Antibody discovery company offering its B-Body bispecific and T-Body trispecific platforms to partners, including for multispecific antibody-drug conjugates. | Booth Exhibiting at Booth 108 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm From Bi- to Trispecific Antibodies: Reimagining the Next Generation of ADCs Antibodies that carry a cell-killing drug and bind several tumor targets, so tumors cannot escape by losing just one. ADCs & conjugatesBispecifics & multispecifics |
Hummingbird Bioscience Singapore | |
Develops antibody therapeutics and antibody-drug conjugates for cancer and autoimmune diseases. | Talk Wed Dec 16 5:15pm–5:45pm Novel, Next-generation ADCs for Autoimmune and Inflammatory Diseases How antibodies carrying a drug payload could be aimed at the immune cells driving inflammation, not just at cancer. Beyond oncology |
Memorial Sloan Kettering Cancer Center New York, NY | |
Cancer treatment and research center in New York City. | Talk Wed Dec 16 3:15pm–3:45pm DLL3 Antibody-Based Radiotheranostics: From ImmunoPET to Targeted Radioligand Therapy Antibodies carrying radioactive tags to both image and treat neuroendocrine tumors, and to pick the patients likely to respond. |
Merck Rahway, NJ | |
Global pharmaceutical company, known as MSD outside the US and Canada, developing medicines, vaccines and biologics. | Talk Wed Dec 16 4:45pm–5:15pm uPAR Targeting Cytotoxic Antibody Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications Using single-cell data to pick a marker on inflammatory immune cells in rheumatoid arthritis, then killing those cells with a drug-carrying antibody. Beyond oncology |
Develops pH-responsive polymer nanoparticles that release drugs in the acidic tumor environment, including the MMAE conjugate ONM-421. | Talk Wed Dec 16 2:45pm–3:15pm Antigen-Independent Antitumor Activity of ONM-421, a pH-Responsive Polymer–Drug Conjugate Delivering MMAE to Solid Tumors A polymer that releases its chemotherapy payload in the acidic environment around tumors, working without needing a tumor marker to bind. |
Tacalyx Berlin, Germany | |
Max Planck spin-out developing antibodies and antibody–drug conjugates against tumor-associated carbohydrate antigens. | Talk Tue Dec 15 11:00am–11:30am High Co-crosslinking of Surface Proteins by Anti-carbohydrate Antibodies for Rapid Internalization and Efficient Payload Delivery Antibodies against tumor sugar structures that clump many surface proteins together, so cells swallow them fast and take up a drug payload. ADCs & conjugates |
Trio Pharmaceuticals San Diego, CA | |
Develops bispecific antibodies and bispecific antibody–drug conjugates that target both cancer cells and immunosuppressive cells in tumors. | Talk Wed Dec 16 11:00am–11:30am TIE-ADC™: A Bispecific ADC Platform Eliminating Cancer Cells and Tumor Immunosuppressor Cells to Enhance Anti-Tumor Immunity A drug-carrying antibody that binds both a tumor marker and a marker on immune-suppressing cells, killing both with one payload. ADCs & conjugates |
Washington University School of Medicine St. Louis, MO | |
Medical school of Washington University in St. Louis. | Talk Wed Dec 16 2:10pm–2:15pm |
Lonza Basel, Switzerland | |
Contract development and manufacturing organization for biologics, including antibodies and bioconjugates. | Booth Exhibiting at Booth T10 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 12:35pm–1:05pm Lonza Scientific Briefing Developability & CMC |
WuXi Biologics Wuxi, China | |
Contract research, development and manufacturing organization for biologics, including antibodies, bispecifics and antibody–drug conjugates. | Booth Exhibiting at Booth 209 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:15pm–1:45pm |
Asymchem Tianjin, China | |
Contract development and manufacturing organization for small molecules, biologics and bioconjugates. | Booth Exhibiting at Booth 518 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm |
NJ Bio Princeton, NJ | |
Contract research and manufacturing organization specializing in antibody–drug conjugates, bioconjugation and linker-payload chemistry, from discovery through GMP manufacturing. | Booth Exhibiting (no floor booth listed) Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm |
Instantly find 20 buyers in adcs & conjugates
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect, The Antibody Society or Antibody Engineering & Therapeutics. Submit a correction